Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis

Next Previous
X
Search
Trial Profile

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Volixibat (Primary)
  • Indications Intrahepatic cholestasis; Primary sclerosing cholangitis
  • Focus Registrational; Therapeutic Use
  • Acronyms VISTAS
  • Sponsors Mirum Pharmaceuticals

    • Most Recent Events

    • 17 Jun 2024 According to a Mirum Pharmaceuticals media release, interim analysis for the VISTAS PSC study was conducted and the independent data review committee recommended that the study continue with the selected volixibat dose of 20 mg twice daily, with no changes to the study. The criteria for continuation included safety as well as a predefined threshold for efficacy. The sponsor and investigators are blinded to the interim results and analysis.
    • 17 Jun 2024 According to a Mirum Pharmaceuticals media release, the company to host a conference call to discuss a interim analysis of VISTAS and VANTAGE on Monday, June 17 at 8:30 a.m. ET/5:30 a.m. Kris Kowdley is investigator in this trial.
    • 08 May 2024 According to a Mirum Pharmaceuticals media release, interim analysis expected in June of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top